1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Samsung Biologics Co.,Ltd.
  6. News
  7. Summary
    A207940   KR7207940008

SAMSUNG BIOLOGICS CO.,LTD.

(A207940)
  Report
End-of-day quote Korea Stock Exchange  -  05-18
796000.00 KRW   +0.38%
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies; SK Hynix Loses 2%
MT
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

S.Korean stocks post best day in 6 weeks on Powell remarks

01/12/2022 | 02:14am EDT

* KOSPI rises, foreigners net buyers

* Korean won strengthens against U.S. dollar

* South Korea benchmark bond yield falls

* For the midday report, please click

SEOUL, Jan 12 (Reuters) - Round-up of South Korean financial markets:

** South Korean shares marked their best day in six weeks on Wednesday, as investors appeared pleased with a less-hawkish stance by the U.S. Federal Reserve Chair Jerome Powell. The Korean won strengthened, while the benchmark bond yield fell.

** The benchmark KOSPI ended up 45.10 points, or 1.54%, at 2,972.48, logging the sharpest rise since Dec. 2.

** Most heavyweights gained, with Samsung Biologics and Naver rising 2.88% and 3.13%, respectively, while LG Chem added 5.31%.

** The KOSPI index tracked overnight gains on Wall Street after Powell pledged to tackle inflation to support economic growth and said the U.S. central bank was ready for the start of tighter monetary policy.

** Meanwhile, a Reuters poll showed the Bank of Korea is seen raising its policy rate to 1.25% at its Friday meeting to restrain inflationary risks and the increasing debt that households are taking on to buy property.

** Investor focus was also on U.S. December inflation data expected later in the day, with headline CPI seen coming in at a red-hot 7% on a year-on-year basis.

** Foreigners were net buyers of 452 billion won ($379.67 million) worth of shares on the main board.

** The won ended at 1,190.5 per dollar on the onshore settlement platform, 0.35% higher than its previous close. The unit strengthened to its highest level in more than one week.

** In offshore trading, the won was quoted at 1,190.4, while in non-deliverable forward trading its one-month contract was quoted at 1,190.9.

** In money and debt markets, March futures on three-year treasury bonds rose 0.12 point to 108.47.

** The most liquid 3-year Korean treasury bond yield fell by 3.4 basis points to 2.004%, while the benchmark 10-year yield dropped by 5.1 basis points to 2.434%.

($1 = 1,190.5000 won) (Reporting by Joori Roh; Editing by Sherry Jacob-Phillips)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
KOSPI COMPOSITE INDEX 1.94% 2638.73 Real-time Quote.-13.03%
LG CHEM, LTD. -1.95% 502000 End-of-day quote.-18.37%
LG CORP. -1.06% 74400 End-of-day quote.-8.03%
NAVER CORPORATION -1.81% 271500 End-of-day quote.-28.27%
ON SEMICONDUCTOR CORPORATION -2.03% 54.9 Delayed Quote.-17.45%
SAMSUNG BIOLOGICS CO.,LTD. 0.38% 796000 End-of-day quote.-11.85%
SAMSUNG ELECTRONICS CO., LTD. -0.88% 67500 End-of-day quote.-13.79%
SK HYNIX INC. -2.20% 111000 End-of-day quote.-15.27%
All news about SAMSUNG BIOLOGICS CO.,LTD.
05/16South Korea’s Leading Index Kospi Slips on Fears over Rate Hikes Across Economies..
MT
04/29SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
04/28South Korea’s Kospi Adds 1% on Stellar Q1 Earnings; Samsung Biologics Adds 3%
MT
04/28Samsung Biologics' Net Income Surges 141% in March Quarter
MT
04/28Samsung Biologics Completes Full Acquisition Of Samsung Bioepis
AQ
04/27SAMSUNG BIOLOGICS : Material Business Matters Related to Investment Decisions
PU
04/21SAMSUNG BIOLOGICS : Results of issuance (Voluntary Disclosure)
PU
04/05Allakos Inc. Enters into A Master Development Services Agreement with Samsung Biologics..
CI
04/01Samsung C&T - Samsung Life Science Fund makes first investment in US biotech firm Jagua..
AQ
03/30SAMSUNG BIOLOGICS : Decision on Acquisition of Tangible Assets
PU
More news
Analyst Recommendations on SAMSUNG BIOLOGICS CO.,LTD.
More recommendations
Financials
Sales 2022 1 991 B 1,57 B 1,57 B
Net income 2022 542 B 0,43 B 0,43 B
Net Debt 2022 566 B 0,45 B 0,45 B
P/E ratio 2022 102x
Yield 2022 -
Capitalization 57 509 B 45 395 M 45 395 M
EV / Sales 2022 29,2x
EV / Sales 2023 25,6x
Nbr of Employees 2 886
Free-Float 25,6%
Chart SAMSUNG BIOLOGICS CO.,LTD.
Duration : Period :
Samsung Biologics Co.,Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAMSUNG BIOLOGICS CO.,LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Mean consensus -
Number of Analysts 0
Last Close Price 808 000,00
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
John Chongbo Rim President, Chief Executive Officer & Director
Tae-Han Kim Chairman
Yong-Ho An Managing Director & Head-Process Technology
Hyung-Woo Moon Head-Compliance Support
Seok-Woo Jung Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SAMSUNG BIOLOGICS CO.,LTD.-11.85%44 721
CSL LIMITED-5.75%93 171
BIOGEN INC.-19.52%28 278
WUXI BIOLOGICS (CAYMAN) INC.-43.60%28 063
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-26.31%21 889
UCB-11.65%17 758